Editor's Choice
[Preprint] A large-scale observational study in Chile found CoronaVac (an inactivated SARS-CoV-2 vaccine) was associated with an effectiveness of 74.5% against infection, 91.0% against hospitalization, and 93.8% against ICU admission in children aged 6 to 16 years.
22 Feb, 2022 | 09:58h | UTCCommentary: Full schedule of CoronaVac vaccine shown to be highly effective in children – News Medical
Raw and cooked vegetable consumption and risk of cardiovascular disease: a study of 400,000 adults in UK Biobank.
22 Feb, 2022 | 09:51h | UTCCommentaries:
Eating veggies won’t protect your heart, study says, but critics disagree – CNN
Study Finds No Heart Benefit From Veggies. Nutritionists Disagree – HealthDay
ESCMID rapid guidelines for assessment and management of long COVID.
21 Feb, 2022 | 09:31h | UTCRelated:
ERS statement on Long COVID-19 follow-up.
Proposed subtypes of long-Covid and their respective potential therapies.
EuGMS Guidance: Management of post-acute COVID-19 patients in geriatric rehabilitation.
Addressing Post-COVID Symptoms: A Guide for Primary Care Physicians.
Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the ‘long-haulers’.
Systematic Review: Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection.
WHO Consensus: A clinical case definition of post COVID-19 condition (Long Covid).
Characterizing long COVID: a living systematic review.
Long Covid – The illness narratives.
New guidelines to help doctors manage long COVID patients published.
M-A: More than 50 long-term effects of COVID-19. (several articles on the subject)
RCT: In patients with mild to moderate Covid-19 and comorbidities, treatment with Ivermectin did not reduce the risk of disease progression.
21 Feb, 2022 | 09:34h | UTCCommentaries:
Ivermectin doesn’t prevent severe disease from Covid-19, new study finds – CNN
Ivermectin futile for mild to moderate COVID-19, study finds – CIDRAP
Related:
Case Series: Toxic effects from ivermectin use associated with prevention and treatment of Covid-19.
Long-term consequences of the misuse of ivermectin data.
Ivermectin: How false science created a Covid ‘miracle’ drug.
Fraudulent ivermectin studies open up new battleground between science and misinformation.
The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.
Ivermectin: Cochrane’s most talked about review so far, ever. Why?
Flawed ivermectin preprint highlights challenges of COVID drug studies.
Systematic review: no evidence to support the use of Ivermectin for treating or preventing COVID-19.
Why was a major study on ivermectin for covid-19 just retracted?
RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.
RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19
RCT: Advising overweight patients to increase sleep duration may reduce caloric intake.
21 Feb, 2022 | 09:27h | UTCNews Release: Getting more sleep reduces caloric intake, a game changer for weight loss programs – University of Chicago Medical Center
Commentaries:
Cut nearly 300 calories a day by doing something you already do – CNN
Individualized Sleep Counseling Can Aid Weight Loss in Overweight – HealthDay
Commentary on Twitter
In this randomized clinical trial of overweight adults who habitually sleep <6.5 hours per night, sleep extension reduced daily energy intake by ~270 kcal. Maintaining adequate sleep duration could be a viable intervention to prevent or reverse obesity. https://t.co/4nURTFSMO0 pic.twitter.com/jXaRx7wOdG
— JAMA Internal Medicine (@JAMAInternalMed) February 7, 2022
Review | Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus.
21 Feb, 2022 | 09:30h | UTCLong COVID: post-acute sequelae of COVID-19 with a cardiovascular focus – European Heart Journal
News Release: Review highlights impact of Long COVID on cardiovascular system – University of Oxford
Related:
The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.
COVID-19 infections increase risk of heart conditions up to a year later, study finds.
Perspective | Is it time to live with COVID-19? Some scientists warn of ‘endemic delusion’.
21 Feb, 2022 | 09:28h | UTCIs it time to live with COVID-19? Some scientists warn of ‘endemic delusion’ – Science
Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis.
21 Feb, 2022 | 09:33h | UTC
Surgery students ‘losing dexterity to stitch patients’.
21 Feb, 2022 | 09:24h | UTCSurgery students ‘losing dexterity to stitch patients’ – BBC
ERAS/SVS Consensus Statement on perioperative care in open aortic vascular surgery.
21 Feb, 2022 | 09:21h | UTC
New U.S. childhood and adolescent immunization schedule released by ACIP.
18 Feb, 2022 | 10:05h | UTCRecommended Childhood and Adolescent Immunization Schedule: United States, 2022 – Pediatrics
See also:
New U.S. adult immunization schedule released by ACIP.
18 Feb, 2022 | 10:07h | UTCRecommended Adult Immunization Schedule, United States, 2022 – Annals of Internal Medicine
Cohort Study: Risks of mental health outcomes in people with covid-19.
18 Feb, 2022 | 10:02h | UTCRisks of mental health outcomes in people with covid-19: cohort study – The BMJ
Editorial: Mental health after covid-19 – The BMJ
News release: Study suggests increased risk of mental health disorders after COVID-19 infection – BMJ
Commentaries:
Mental health in people with covid-19 – The BMJ
Large study reveals clearer links between COVID-19, mental health risks – CIDRAP
Another study suggests a lower risk of hospitalization and death from infection with SARS-CoV-2 Omicron variant vs. Delta.
18 Feb, 2022 | 10:01h | UTCEstimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada – JAMA
The pathogenesis and long-term consequences of Covid-19 cardiac injury: state-of-the-art review.
18 Feb, 2022 | 09:56h | UTCRelated: COVID-19 infections increase risk of heart conditions up to a year later, study finds.
WHO Interim Guidance: Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant.
18 Feb, 2022 | 09:59h | UTC
Commentary on Twitter (thread – click for more)
#COVID19 quarantine period may be shortened for contacts who test negative on a PCR or antigen based rapid diagnostic test. Quarantine can be shortened, for example to seven days, if the contact shows no symptoms & presents a negative test https://t.co/ERF0HDcJOU https://t.co/TsbcHw86B7
— World Health Organization (WHO) (@WHO) February 17, 2022
Opinion | Coronaviruses are ‘clever’: Evolutionary scenarios for the future of SARS-CoV-2.
18 Feb, 2022 | 09:54h | UTCCoronaviruses are ‘clever’: Evolutionary scenarios for the future of SARS-CoV-2 – STAT
Perspective: We’re entering the control phase of the pandemic.
18 Feb, 2022 | 08:49h | UTCWe’re Entering the Control Phase of the Pandemic – The Atlantic
RCT: Darolutamide and survival in metastatic, hormone-sensitive prostate cancer.
18 Feb, 2022 | 08:47h | UTC
Commentary on Twitter
Adding darolutamide to androgen-deprivation therapy and docetaxel significantly increased overall survival among patients with metastatic, hormone-sensitive prostate cancer. #GU22 https://t.co/GkQZdKgtJs pic.twitter.com/3e5S7tW1Zw
— NEJM (@NEJM) February 17, 2022
Global, regional, and national prevalence estimates of physical or sexual, or both, intimate partner violence against women.
18 Feb, 2022 | 08:44h | UTCNews release: More than a quarter of women have experienced intimate partner violence in their lifetimes, finds new study – The Lancet
Commentary: Intimate partner violence against women: a persistent and urgent challenge – The Lancet
Commentary on Twitter (thread – click for more)
NEW—Over 1 in 4 women have experienced intimate partner violence in their lifetimes, study finds.
Authors highlight urgent need to strengthen the public health response in post-COVID-19 reconstruction efforts. https://t.co/yZ61fqIZlV pic.twitter.com/AeMSicRUY0
— The Lancet (@TheLancet) February 17, 2022
Cohort study: Protection against SARS-CoV-2 after Covid-19 vaccination lasts longer in patients with previous infection.
17 Feb, 2022 | 10:11h | UTC
RCT: Oral Nirmatrelvir for high-risk adults with Covid-19 reduces the risk of hospitalization by 89%.
17 Feb, 2022 | 10:14h | UTCAudio Interview: A New Antiviral against Covid-19 – new England Journal of Medicine
Related:
Commentary on Twitter
The Paxlovid pill (Nirmatrelvir) randomized, placebo-controlled trial published @NEJM:
89% efficacy vs Covid hospitalizations or deaths, and quick reduction of viral load.
The active pills had less serious adverse events or discontinuations than placebohttps://t.co/HBMRZt4wBo pic.twitter.com/LDQv41O56c— Eric Topol (@EricTopol) February 16, 2022
Retrospective cohort study: Pfizer vaccine reduces the risk of reinfection after recovery from Covid-19.
17 Feb, 2022 | 10:13h | UTCEffectiveness of the BNT162b2 Vaccine after Recovery from Covid-19 – New England Journal of Medicine
Commentary on Twitter
Among patients who had recovered from Covid-19, the receipt of at least one dose of the BNT162b2 vaccine was associated with a significantly lower risk of recurrent infection. https://t.co/AAlsY9sFlv pic.twitter.com/Nkj1lP77ZW
— NEJM (@NEJM) February 16, 2022
Meta-analysis finds the overall prevalence of statin intolerance is around 9% and identifies the most common risk factors.
17 Feb, 2022 | 10:07h | UTCPrevalence of statin intolerance: a meta-analysis – European Heart Journal
Commentaries:
Expert reaction to study looking at statin intolerance – Science Media Centre
Related:
Commentary on Twitter
Statin intolerance is “over-estimated and over-diagnosed”. World’s largest study shows less than 10% suffer side-effects caused by statins https://t.co/pcVk8YI3I3@escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes #CVD #Riskfactors pic.twitter.com/b3nFWsc74d
— European Society of Cardiology Journals (@ESC_Journals) February 16, 2022
England to offer Covid jab to five to 11-year-olds.
17 Feb, 2022 | 10:09h | UTCEngland to offer Covid jab to five to 11-year-olds – BBC